Search

The first patient has been enrolled in Part 2 of the Phase 1b/2a clinical trial of SNIPR001, an investigational CRISPR-armed phage therapeutic candidate for preventing E. coli bloodstream infections in hematopoietic stem cell transplant pat

Armata Pharmaceuticals announced on September 14, 2026 that the US FDA has granted Breakthrough Therapy designation to AP-SA02, its intravenous multi-phage product candidate for adjunct treatment of complicated Staphylococcus aureus bactere

MicrobiotiX reported completion of the sentinel cohort in its Phase 1 MP101 trial for Pseudomonas aeruginosa pneumonia. The initial 72-hour assessment raised no safety concern that prevented continuation, and Cohort 1 enrollment was proceed

Armata said it was finalizing activities for a pivotal Phase 3 superiority study of AP-SA02 in complicated Staphylococcus aureus bacteremia, anticipated to start in the second half of 2026. Armata Pharmaceuticals

Dr. Gregory German of Unity Health Toronto will lead P-PEAKS UTI, an international clinical trial in which about 220 women with E. coli urinary tract infections lasting a year or more will receive either personalized phage therapy or placeb

The REPhRAME project, coordinated by Universitätsmedizin Frankfurt under Prof. Maria J.G.T. Vehreschild, has been awarded €15 million through Horizon Europe; it began in June 2026 and is planned to run for five years. It will assess in a ra

PHAGE4DAIR, a Horizon Europe project coordinated by Qeen Biotechnologies (Canada), runs from 1 June 2026 to 31 May 2031 with an EU contribution of €14,869,038.73. It is a multicenter, randomized, double-blind, placebo-controlled, adaptive P

Tristan Ferry discusses PHAGEinLYON’s clinical experience with compassionate use and clinical trials in a talk hosted on Canal-U. Phages.fr on Canal-U

Final results of the randomized, placebo-controlled, double-blind Phase 1 trial of oral SNIPR001 in healthy volunteers were published in The Lancet Microbe. The trial evaluated safety and tolerability after twice-daily dosing for seven days

Armata Pharmaceuticals announced on January 13, 2026 an FDA End-of-Phase 2 written response confirming that safety and efficacy data from its Phase 2a diSArm study support advancing AP-SA02, an intravenous S. aureus bacteriophage cocktail,

A $3.3 million NIAID contract supports a proof-of-concept clinical trial of LBP-PA01 for pneumonia, with further funding conditional on milestones. www.locus-bio.com

UMC Utrecht has received a 4 million euro grant from the Promising Care scheme of the National Healthcare Institute and ZonMw for the first clinical study in the Netherlands of customized bacteriophage therapy for recurrent urinary tract in

BiomX announced on December 8, 2025 that it was discontinuing its Phase 2b trial of BX004 in cystic fibrosis patients with chronic Pseudomonas aeruginosa infections, saying the time and resources needed for the alternative dosing strategy r

MicrobiotiX, a Korean bacteriophage-therapy company, completed an extended Series B totaling 20 billion KRW (29 billion KRW raised across rounds). It was also selected for the Korean Ministry of Health and Welfare's Infectious Disease Preve

Jessica was interviewed on the Development & Research podcast, a new video interview series by biotech investor/economist Ross Rheingans-Yoo about people doing things differently in clinical trials and drug development. They discussed oper

In a Form 8-K dated August 19, 2025, BiomX reported that the FDA placed a clinical hold on its Phase 2b study of BX004 in cystic fibrosis while it reviews data on a third-party nebulizer used to deliver BX004. The FDA raised no concerns abo

SNIPR Biome announced on June 12, 2025 that the first patient has been dosed in its Phase 1b study of SNIPR001, an orally administered CRISPR-armed phage therapeutic that targets E. coli in the gut, in hematological cancer patients undergoi

A team of authors from Israel and Portugal, including researchers from the Hadassah Medical Organization, tested the bacteriophage mixture TP-102 on 19 diabetic patients with infected and non-infected foot ulcers. TP-102 was safe and well t

Another successful phage therapy clinical trial! Armata Pharmaceuticals and colleagues has announced positive topline results from its Phase 1b/2a trial of AP-SA02 for S. aureus bacteremia.

The European Commission’s 2025 call sought multicentre, multinational randomised trials of phage therapies for difficult-to-treat bacterial infections, alone or alongside standard care. The call is closed; its deadline was September 16, 202